Transaction DateRecipientSharesTypePriceValue
30th December 2020Thomas Woiwode1,347,709Open or private purchase$3.71$5,000,000.39
14th December 2020Thomas Woiwode12,783Other acquisition or disposition$0.00
20th October 2020Thomas Woiwode198,485Conversion of derivative$0.00
20th October 2020Thomas Woiwode200,000Open or private purchase$15.00$3,000,000.00
20th October 2020Thomas Woiwode463,959Conversion of derivative$0.00
20th October 2020Thomas Woiwode198,839Conversion of derivative$0.00
20th October 2020Thomas Woiwode2,145,991Conversion of derivative$0.00
20th October 2020Thomas Woiwode85,065Conversion of derivative$0.00
17th August 2020Erin Jones10,000Exercise of derivative$0.35$3,450.00
3rd March 2020Thomas Woiwode1,049,175Conversion of derivative$0.00
Gritstone Oncology
Gritstone Oncology logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Gritstone Oncology, Inc. is a clinical-stage biotechnology company. The company is developing the next generation of cancer immunotherapies to fight multiple cancer types.

Ticker: GRTS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1656634
Employees: 174
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $63 M (0%)
Marketable Securities, Current: $29 M (-58%)
Other Assets, Current: $290 Th (0%)
Assets, Current: $94 M (-28%)
Property, Plant and Equipment, Net: $25 M (0%)
Assets: $146 M (-21%)
Accounts Payable, Current: $4 M (-6%)
Accrued Liabilities, Current: $138 Th (-86%)
Liabilities, Current: $19 M (-1%)
Liabilities: $49 M (-1%)
Common Stock, Value, Issued: $17 Th (0%)
Common Stock, Shares, Issued: $38 M (0%)
Retained Earnings (Accumulated Deficit): $273 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $50 Th (108%)
Stockholders' Equity (Parent): $96 M (0%)
Liabilities and Equity: $146 M (-21%)
Revenue: $488 Th (-72%)
Research and Development: $21 M (-51%)
General and Administrative Expenses: $5 M (-50%)
Operating Income/Loss: $26 M (-50%)